STOCK TITAN

Director at Alamar Biosciences (NASDAQ: ALMR) updates stock option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Alamar Biosciences director Rebecca Chambers reported an internal restructuring of stock options, not an open-market trade. One option covering 140,612 shares of Common Stock at an exercise price of $7.60 per share is now recorded as outstanding, while a corresponding option tied to 140,612 shares of Class B Common Stock was removed.

Each share of Class B Common Stock was reclassified into one share of Common Stock immediately before the company’s initial public offering, and the option reflects that change. Twenty-five percent of the option vests on January 15, 2027, with the remaining shares vesting in equal monthly installments over the following three years, and the option expires on January 14, 2036.

Positive

  • None.

Negative

  • None.
Insider Chambers Rebecca
Role null
Type Security Shares Price Value
Other Stock Option (Right to Buy) 140,612 $0.00 --
Other Stock Option (Right to Buy) 140,612 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null)
Footnotes (1)
  1. Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.
Option size 140,612 shares Stock option over Common Stock reported for Rebecca Chambers
Underlying Class B option removed 140,612 shares Class B Common Stock option position reduced to zero
Exercise price $7.60 per share Exercise price for the reported stock option
Expiration date January 14, 2036 Option term end for Chambers’ stock option
Initial vesting date January 15, 2027 25% of option shares vest on this date
Restructured shares total 281,224 shares Shares involved in restructuring transactions coded J
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy) with 140,612 shares"
Class B Common Stock financial
"underlying_security_title: Class B Common Stock with 140,612 shares"
A class B common stock is one of multiple types of a company’s ordinary shares that carries specific rights—often different voting power or dividend priority—compared with other classes. For investors it matters because those differences affect how much influence you have over company decisions, the income you might receive, and how freely the shares trade; think of it like owning a car with different keys: some keys let you start the engine and open the trunk, others only unlock the door.
initial public offering financial
"reclassified into one share of Common Stock immediately prior to the completion of the initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
vest financial
"Twenty-five percent of the shares subject to the option vest on January 15, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
transaction code J financial
"transaction_code: J, described as Other acquisition or disposition"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chambers Rebecca

(Last)(First)(Middle)
C/O ALAMAR BIOSCIENCES, INC.
47071 BAYSIDE PARKWAY

(Street)
FREMONT CALIFORNIA 94538

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Alamar Biosciences, Inc. [ ALMR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$7.604/20/2026J(1)140,612 (2)01/14/2036Class B Common Stock140,612$00D
Stock Option (Right to Buy)$7.604/20/2026J(1)140,612 (2)01/14/2036Common Stock140,612$0140,612D
Explanation of Responses:
1. Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
2. Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.
/s/ Timothy White, Attorney-in-Fact04/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Alamar Biosciences (ALMR) report for Rebecca Chambers?

Alamar Biosciences reported that director Rebecca Chambers restructured stock options covering 140,612 shares. The filing shows an option over Common Stock recorded as outstanding and a corresponding Class B Common Stock option removed, with no market purchase or sale of shares disclosed.

Did Rebecca Chambers buy or sell Alamar Biosciences (ALMR) shares in this filing?

The filing does not show Rebecca Chambers buying or selling shares in the market. It reports an internal option restructuring using transaction code J, categorized as “other acquisition or disposition,” with net shares unchanged and no open-market purchase or sale activity indicated.

How many Alamar Biosciences (ALMR) shares are covered by Rebecca Chambers’ option?

The reported stock option covers 140,612 shares of Alamar Biosciences Common Stock. A corresponding 140,612-share Class B Common Stock option was removed, reflecting a reclassification, so the overall economic exposure through this option remains based on 140,612 underlying shares.

What is the exercise price and expiration date of the Alamar Biosciences (ALMR) option?

The stock option reported for Rebecca Chambers has an exercise price of $7.60 per share and expires on January 14, 2036. These terms define the price she would pay to acquire shares and how long the option remains available before it lapses.

How does the Alamar Biosciences (ALMR) option for Rebecca Chambers vest?

The option vests 25% of its shares on January 15, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. Vesting depends on Rebecca Chambers’ continuous service with the company through each scheduled vesting date.

Why does the Alamar Biosciences (ALMR) filing mention Class B Common Stock?

The filing explains that each share of Class B Common Stock was reclassified into one share of Common Stock immediately before the company’s initial public offering. The option records this reclassification by shifting from a Class B Common Stock underlying security to Common Stock.